COMMUNIQUÉ DE PRESSE publié le 20/03/2024 à 09:50, il y a 8 mois 1 jour MindBio Begins Landmark Phase 2B Take-Home Microdosing (MB22001) Clinical Trial in Patients with Major Depressive Disorder Phase 2B trial begins with MB22001 for Major Depressive Disorder patients. Successful Phase 2A trial showed 53% in remission with 14.1 MADRS score drop. MindBio aims to scale up psychedelic treatment for depression MB22001 Major Depressive Disorder Phase 2b MindBio Psychedelic Treatment
COMMUNIQUÉ DE PRESSE publié le 20/03/2024 à 09:50, il y a 8 mois 1 jour MindBio Begins Landmark Phase 2B Take-Home Microdosing (MB22001) Clinical Trial in Patients with Major Depressive Disorder MindBio Therapeutics Corp. commences Phase 2B clinical trial for MB22001 in Major Depressive Disorder patients, following successful Phase 2A trial with significant results Psychedelic Medicine MindBio Therapeutics Corp. MB22001 Major Depressive Disorder Clinical Trial
BRÈVE publiée le 04/03/2024 à 11:05, il y a 8 mois 17 jours MindBio Therapeutics passe à l'essai de phase 2B pour la médecine psychédélique dans le trouble dépressif majeur MindBio Thérapeutique Trouble Dépressif Majeur Essai Clinique De Phase 2B Médecine Psychédélique Microdosage Du LSD
BRÈVE publiée le 04/03/2024 à 11:05, il y a 8 mois 17 jours MindBio Therapeutics Advances to Phase 2B Trial for Psychedelic Medicine in Major Depressive Disorder Psychedelic Medicine Major Depressive Disorder Microdosing LSD Phase 2b Clinical Trial MindBio Therapeutics
COMMUNIQUÉ DE PRESSE publié le 04/03/2024 à 11:00, il y a 8 mois 17 jours MindBio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomised Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder Ethics and regulatory approvals finalized for world-first take-home use of psychedelic medicine MB22001 in Phase 2B randomized controlled trial for Major Depressive Disorder by MindBio Therapeutics Corp Psychedelic Medicine MB22001 Major Depressive Disorder MindBio Therapeutics Phase 2B Trial
BRÈVE publiée le 26/02/2024 à 10:30, il y a 8 mois 24 jours MindBio annonce des résultats positifs dans un essai clinique de microdosage à domicile pour la dépression Depression MB22001 Essai Clinique MindBio Microdosage
BRÈVE publiée le 26/02/2024 à 10:30, il y a 8 mois 24 jours MindBio Announces Positive Results in At-Home Microdosing Clinical Trial for Depression Depression MB22001 MindBio Microdosing Clinical Test
COMMUNIQUÉ DE PRESSE publié le 26/02/2024 à 10:30, il y a 8 mois 24 jours MindBio Therapeutics Announces Positive Depression Data from World-First Phase 2a Take-Home Microdosing Trial MindBio announces positive top line data from its world-first take-home microdosing depression clinical trial using MB22001. Patients experienced a 60% reduction in depressive symptoms with an impressive mean 14.1 point drop in MADRS score over 8 weeks Psychedelic Medicine Depression MB22001 Clinical Trial MindBio
COMMUNIQUÉ DE PRESSE publié le 14/02/2024 à 10:00, il y a 9 mois 7 jours MindBio Therapeutics Completes World First Take Home Phase 2a Microdosing Depression Trial MindBio Therapeutics Corp. completes landmark Phase 2a clinical trial in Major Depressive Disorder patients with regulatory approvals for take-home use of proprietary microdose LSD MB22001. Phase 2B trial in late-stage cancer patients ongoing. CEO Justin Hanka announces pivotal moment for psychiatric medicine development MindBio Therapeutics Corp. Major Depressive Disorder Clinical Trial Phase 2a LSD Microdosing
COMMUNIQUÉ DE PRESSE publié le 30/01/2024 à 08:10, il y a 9 mois 22 jours MindBio Therapeutics Nears Completion of Landmark Phase 2a LSD Microdosing (MB22001) Clinical Trial in Depressed Patients MindBio Therapeutics Corp. is nearing completion of its Phase 2a clinical trial using MB22001 in patients with Major Depressive Disorder. The company expects top line results to be announced in March 2024. MindBio is conducting trials with regulatory approvals for take-home use of a special form of LSD in microdoses, aiming to treat mental health conditions MindBio Therapeutics Corp. Phase 2a Clinical Trial MB22001 Major Depressive Disorder Microdosing LSD
Publié le 21/11/2024 à 06:58, il y a 16 heures 9 minutes Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 16 heures 9 minutes Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 16 heures 9 minutes Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Publié le 20/11/2024 à 20:07, il y a 1 jour 3 heures Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Publié le 20/11/2024 à 19:20, il y a 1 jour 3 heures Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Publié le 21/11/2024 à 22:05, il y a 1 heure 2 minutes Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Publié le 21/11/2024 à 21:50, il y a 1 heure 17 minutes Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Publié le 21/11/2024 à 20:15, il y a 2 heures 52 minutes Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Publié le 21/11/2024 à 20:10, il y a 2 heures 57 minutes For Us TV Productions, a Portfolio Company of Belle Bonica Luxe Corp., Invites BIPOC Filmmakers and Producers to Join Its Inclusive Streaming Platform
Publié le 21/11/2024 à 20:00, il y a 3 heures 7 minutes Victory for New York Homeowners: Petroff Amshen LLP Blocks Lender’s Repeated Foreclosure Attempt
Publié le 21/11/2024 à 19:01, il y a 4 heures 6 minutes Fuller, Smith & Turner PLC: Transaction in own shares
Publié le 21/11/2024 à 18:36, il y a 4 heures 31 minutes Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Publié le 21/11/2024 à 17:58, il y a 5 heures 9 minutes Funding Circle Plc: POS-Transaction in Own Shares
Publié le 21/11/2024 à 17:51, il y a 5 heures 16 minutes LIGHTON announces highly successful IPO on Euronext Growth Paris.
Publié le 21/11/2024 à 17:51, il y a 5 heures 16 minutes LIGHTON annonce le vif succès de son introduction en Bourse sur Euronext Growth Paris.